What's hot!

View all perspectives
What's Hot

Dietary Interventions in PsA

Dr. Peter Nash reports on several abstracts at the 2026 EULAR meeting in London, including: OP069; OP070 and POS0050.

Watch video →

Low dose Blinatumomab: Many Relapse with an Unexpected Surprise

Dr. Alfred Kim discusses abstract OP0203 presented at EULAR 2026 in London. 

Watch video →

Renal Biopsies in SLE

Dr. Andrea Fava reporting from EULAR 2026 in London.

Watch video →

RA BRIDGE and RA BRANCH trials: Baricitinib and VTE Risk

Drs. Mrinalini Dey and Jon Giles discuss abstract LB0009 presented at EULAR 2026 in London 

Watch video →

Combination Biologics in PsA: MRI Findings from AFFINITY

Dr. Artie Kavanaugh reports on abstract OP0186 presented at EULAR 2026 in London.  

Watch video →

Day 4 Recap: EULAR 2026

Join Drs. Jack Cush, Mrinalini Dey, Antoni Chan, and Yuz Yusof. Abstracts discussed included: LB0001 LB0002 LB0003 LB0005 LB0007 LB0009 RA Plenary POS1350.

Watch video →

EULAR 2026 Recommendations: Immunization

Dr. Jiha Lee reporting from EULAR 2026 in London.

Watch video →

Making Methotrexate More Effective

Dr. Jonathan Kay reports on abstract OP0206 and OP0207 presented at EULAR 2026 in London

Watch video →

Are we failing in the treatment of RA-ILD?

Dr. Janet Pope discusses treatment of RA-ILD after attending the "How to Treat (HOT)" session on RA-ILD at EULAR 2026.

Watch video →

How Many CAR-Ts Do We Need to Test Drive?

Dr. Janet Pope reviews CAR-T therapy at 2026 EULAR 2026, and the issues and questions that remain with its use in rheumatology.

Watch video →

Day 3 Recap: EULAR 2026

Join Drs. Jack Cush, Jiha Lee, Nelly Ziade, and Sheila Reyes for a lively discussion. Abstracts discussed included: OP0348 POS0290 OP0342 POS1068 POS0201 POS0288

Watch video →

New axSpA Criteria: Who gets left out?

Dr. Nelly Ziade discusses abstract OP0236, OP0239, and POS0190 EULAR 2026.  

Watch video →

PsA Potpourri: Probiotics & Head-to-Head Data

Dr. Peter Nash reports on abstracts POS0290 and LB0001 at EULAR 2026.

Watch video →
CAR T on purple background

5 years since Patient ID001: Progress on CAR-T Therapy in RMD

Five years on, are we closer to licensing of the first CAR-T therapy in rheumatic and musculoskeletal diseases (RMD)?

Read more →

BMI Outranks Treatment in PsA Outcomes?

Dr. Peter Nash reports on abstract OP0187 presented at EULAR 2026 in London.

Watch video →

BE BOLD: Going Where No PsA Trial Has Gone Before

Dr. Aurelie Najm discusses abstract LB0001 presented at the 2026 EULAR Congress in London  

Watch video →
holding hands together support frail

New biomarkers in RA: Who to treat, Who to watch, Who to taper?

Here is my summary of what EULAR 2026 is presenting to us in the field of biomarker-driven personalized care in RA.

Read more →

Debate: Combination Therapies for Inflammatory Arthritis?

Dr. Jonathan Kay reports on the debate, "Combination of targeted therapies in inflammatory arthritis - is the time now?", from EULAR 2026.

Watch video →
      #OP091 at #EULAR2026: RA was associated with a 44% higher risk of ischaemic stroke versus the general population, with h

      Mrinalini Dey DrMiniDey

      1 week 2 days ago
      #OP091 at #EULAR2026: RA was associated with a 44% higher risk of ischaemic stroke versus the general population, with higher stroke-related mortality and disability. Encouragingly, excess stroke risk was no longer significant in more recent RA cohorts. @RheumNow
      Izokibep IL-17A Affibody PsA

      343 pts RCT PBO crossover wk16
      52 wks data
      ACR50 50–57% ACR70 36–42% PASI100 64% MDA

      Aurelie Najm AurelieRheumo

      1 week 2 days ago
      Izokibep IL-17A Affibody PsA 343 pts RCT PBO crossover wk16 52 wks data ACR50 50–57% ACR70 36–42% PASI100 64% MDA 47–52% No diff between QW vs Q2W AE Injection-site reactions, URTIs most common No new safety signals Looks like any other IL17Ai to me #EULAR2026 #OP073 https://t.co/WiHT8Plitn
      Can we intercept PsA?

      Retro study 394 PSO pts 17 yrs follow-up 86 PsA

      TNFi linked to higher PsA incidence vs IL- MoA
      T

      Aurelie Najm AurelieRheumo

      1 week 2 days ago
      Can we intercept PsA? Retro study 394 PSO pts 17 yrs follow-up 86 PsA TNFi linked to higher PsA incidence vs IL- MoA TNFi 45% vs IL-17i 14% vs IL-23i 10% vs IL-12/23i 11% After adjustment IL-17i HR 0.35 IL-23i HR 0.17 Needs prospective confirmation! #OP072 #EULAR2026 https://t.co/88RaukjLjY
      #OP090 at #EULAR2026: In this nationwide Danish study, RA patients with lung cancer had similar survival outcomes to pat

      Mrinalini Dey DrMiniDey

      1 week 2 days ago
      #OP090 at #EULAR2026: In this nationwide Danish study, RA patients with lung cancer had similar survival outcomes to patients without RA. Importantly, immune checkpoint inhibitor treatment did not appear to worsen outcomes in patients with pre-existing RA. @RheumNow
      At Week 52 with izokibep in #PsA PASI90: 63–69%; PASI100: 55–64%; MDA: 47–52%. The small-molecule format may enabl

      Antoni Chan MD (Prof) synovialjoints

      1 week 2 days ago
      At Week 52 with izokibep in #PsA PASI90: 63–69%; PASI100: 55–64%; MDA: 47–52%. The small-molecule format may enable deeper tissue penetration. Novel anti-IL-17 approach. Abstr#073 @RheumNow #EULAR2026 #Biologics https://t.co/IaJ1gyECZu
      Izokibep (novel small IL-17A inhibitor, 18.6 kDa) maintained efficacy to Week 52 in active #PsA with ~50% of patients ac

      Antoni Chan MD (Prof) synovialjoints

      1 week 2 days ago
      Izokibep (novel small IL-17A inhibitor, 18.6 kDa) maintained efficacy to Week 52 in active #PsA with ~50% of patients achieving ACR50 and nearly half reaching MDA. Sustained durable response with no new safety signals Abstr#OP073 @RheumNow #EULAR2026 https://t.co/Y6fTirE886
      #OP089 at #EULAR2026 provides real-world data on biologic use after new cancer diagnoses in RA. Continuing biologics in

      Mrinalini Dey DrMiniDey

      1 week 2 days ago
      #OP089 at #EULAR2026 provides real-world data on biologic use after new cancer diagnoses in RA. Continuing biologics in early-stage cancer, & restarting them in many stage 2-3 cancers, was not associated with worse 5-year survival in this Japanese registry study. @RheumNow https://t.co/OdCPiCxFEq
      22% of psoriasis patients developed #PsAover 17 years of follow-up. PsA occurred in 44% of TNFi-treated vs only 9–14%

      Antoni Chan MD (Prof) synovialjoints

      1 week 2 days ago
      22% of psoriasis patients developed #PsAover 17 years of follow-up. PsA occurred in 44% of TNFi-treated vs only 9–14% of those on IL-23i or IL-12/23i. Time to discuss "preventive biologics" in PsO? Prospective controlled trials are needed Abstr#072 @RheumNow #EULAR2026
      #EULAR2025 OP0127 Still trying to get my head around the flat line PBO response. In Sjogren pts with ESSDAI=>5, a Pha

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 week 2 days ago
      #EULAR2025 OP0127 Still trying to get my head around the flat line PBO response. In Sjogren pts with ESSDAI=>5, a Phase 3 RCT of Telitacicept (BAFF/APRIL-i) in China met all endpoints. ESSPRI improved too! Could be because strict concom DMARD inc. GC protocol @RheumNow https://t.co/FEhXfNPvfG
      In a 17-year real-world psoriasis cohort, patients on IL-17i had 75% lower odds and IL-23i patients had 84% lower odds o

      Antoni Chan MD (Prof) synovialjoints

      1 week 2 days ago
      In a 17-year real-world psoriasis cohort, patients on IL-17i had 75% lower odds and IL-23i patients had 84% lower odds of developing #PsA vs TNF inhibitors. Is biologic class selection a PsA interception strategy? Prospective controlled trials are needed Abstr#072 @RheumNow https://t.co/jpdZjGK7VV
      #OP088 at #EULAR2026 found that rare deleterious variants in telomere-related genes were associated with increased RA-IL

      Mrinalini Dey DrMiniDey

      1 week 2 days ago
      #OP088 at #EULAR2026 found that rare deleterious variants in telomere-related genes were associated with increased RA-ILD risk, independent of MUC5B status. The effect size was similar to that seen in idiopathic pulmonary fibrosis. @RheumNow
      #Autoimmune #progressive #pulmonary #fibrosis

      Large Spanish registry

      ❎more mortality if not on #DMARDs
      ?underRx of p

      Janet Pope Janetbirdope

      1 week 2 days ago
      #Autoimmune #progressive #pulmonary #fibrosis Large Spanish registry ❎more mortality if not on #DMARDs ?underRx of proven #Rx with #antifibrotics Median survival post #dx #PPF 7.8 yrs Can we do better? #ABST POS0430 @RheumNow #EULAR2026 https://t.co/gP7apxfEPS
      Multiparametric renal MRI in LN:
      Structural MRI can differentiate bet. active and stable dse
      Exudative = active inflamm

      sheila RHEUMarampa

      1 week 2 days ago
      Multiparametric renal MRI in LN: Structural MRI can differentiate bet. active and stable dse Exudative = active inflamm In quanti analysis, low ADC values may reflect fibrosis. A potential non-invasive biomarker? OP092 @rheumNow #EULAR2026 https://t.co/IarTGOen7v
      DIPSA RCT: diet in PsA

      92 pts 3 arms Mediterranean vs DASH low-calorie vs standard advice

      Primary takeaway: amount of

      Aurelie Najm AurelieRheumo

      1 week 2 days ago
      DIPSA RCT: diet in PsA 92 pts 3 arms Mediterranean vs DASH low-calorie vs standard advice Primary takeaway: amount of weight loss matters more than diet! -All groups lost modest weight 1–2.5 kg -All improved similarly in DAPSA -4 to -6 wk 24 -No differences for disease https://t.co/U0cxtdl2Yb
      #OP0112 at #EULAR2026: Real world RISE registry data shows incr use of semaglutide and tirzepatide across RMDs, particul

      Mrinalini Dey DrMiniDey

      1 week 2 days ago
      #OP0112 at #EULAR2026: Real world RISE registry data shows incr use of semaglutide and tirzepatide across RMDs, particularly RA and PsA. Tirzepatide achieved greater weight loss than semaglutide, with ongoing analyses assessing effects on disease activity and function. @RheumNow

      Podcasts

      • RA Topic Podcast compilation
      • PsA Topic Podcast compilation
      • CAR T Topic compilation

      Catch up on Conference Podcasts

      ×